CClinicalTrials.gg
CompletedNCT04701463Updated Jan 8, 2021

A Specialized Amino Acid Mixture on Body Composition and Skin State in Overweight and Obese Class I Postmenopausal Women

An interventional study of L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate and Placebo in Amino Acid, Body Weight Changes and Skin Manifestations, sponsored by Azienda di Servizi alla Persona di Pavia. Completed at 1 site in Italy. Open to female participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-08.

Sponsored by Azienda di Servizi alla Persona di Pavia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jan 2020, registered Jan 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Study summary

The use of dietary amino acids has been explored for therapeutic and safety intervention of obesity and obesity-induced dysfunction. In particular, 3 molecules have been shown to be effective both in the animal model and in humans, in promoting the loss of fat mass, specifically visceral adipose tissue, and in maintaining free fat mass: arginine, glutamine and leucine (and its metabolite beta hydroxy methyl butyrate, HMB). The aim of this study was to evaluate the efficacy in terms of fat mass, in particular Visceral Adipose Tissue reduction, as primary end point, in obese patients following the administration of specific food for special medical purposes (FSMP) for muscle recovery, consisting of arginine, glutamine and HMB. The secondary end point is the evaluation of skin state, by a validate self-reported questionnaire survey to assess skin, after 4- weeks intake of this FSMP.

02

Conditions studied

  • Amino Acid
  • Body Weight Changes
  • Skin Manifestations
  • Obesity
  • Postmenopausal Disorder
03

In context

Overweight

3,670 studies on the registry are indexed under Overweight; 849 are open to participants now.

This study's enrollment of 20 is below the median of 73 across 3,175 interventional studies indexed under Overweight.

Browse Overweight studies →

Lead sponsor

Azienda di Servizi alla Persona di Pavia is the lead sponsor of 27 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Postmenopause
  • Obesity (I class) or overweight

Exclusion criteria

Exclusion Criteria:

  • Taking any medication
  • Having liver, renal and thyroid disease
  • Smoking
  • Drinking more than two standard alcoholic beverages/day (20 g of alcohol/day)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate supplement

    Dietary Supplement: L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate

  • Placebo comparator
    Placebo

    Combination Product: Placebo

Interventions

  • Dietary supplementL-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate

    2 daily sachets (mid morning and mid afternoon) of an oral dietary supplement with L-glutamine and L-arginine and calcium beta-hydroxy-beta-methylbutyrate

  • Combination productPlacebo

    Isocaloric formula

06

What researchers measure

Primary outcomes

  1. Changes on Visceral Adipose Tissue

    Evaluation of Visceral Adipose Tissue (g)

    Time frame: Baseline / 30 days

Secondary outcomes

  1. Changes on Body Composition

    Evaluation of fat mass and fat free mass (g)

    Time frame: Baseline / 30 days

  2. Changes on Metabolic parameters

    Evaluation of Fasting blood glucose (mg/dl), total cholesterol (mg/dl), low-density lipoprotein-cholesterol (mg/dl), high-density lipoprotein-cholesterol (mg/dl) and triglyceride levels (mg/dl)

    Time frame: Baseline / 30 days

  3. Changes on Metabolic parameters

    Evaluation of insulin (mcIU/mL)

    Time frame: Baseline / 30 days

  4. Changes on Metabolic parameters

    Evaluation of insulin resistance (HOMA index)

    Time frame: Baseline / 30 days

  5. Changes on anthropometric measurements

    Evaluation of body weight (kg) and height (m) combined for Body Mass Index (kg/m2)

    Time frame: Baseline / 30 days

  6. Changes on anthropometric measurements

    Evaluation of waist circumference (cm)

    Time frame: Baseline / 30 days

  7. Changes on skin condition

    Administration of a questionnaire survey with a point evaluation scale from 0 to 5 (Oe et al, 2017). For the skin luster and suppleness, one is the worst and five is the best. For the wrinkles, one is least wrinkles; not worry, and five is most wrinkles; most care.

    Time frame: Baseline / 30 days

07

Study locations

1 site
  • Azienda di Servizi alla Persona
    Pavia, 27100, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04701463
Lead sponsor
Azienda di Servizi alla Persona di Pavia
Responsible party
Sponsor
First posted
Jan 8, 2021
Start date
Jan 15, 2020
Primary completion
Nov 3, 2020
Completion
Nov 25, 2020
Last update
Jan 8, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion